The primary objective is to investigate the involvement of the GABA-A receptor in behavioral and neural measures of conscious perception, cognition, and decision-making.
ID
Source
Brief title
Condition
- Other condition
Synonym
Health condition
Geen aandoening, dit onderzoek richt zich op de werking van het gezonde brein.
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Primary study parameters include behavioral reaction times and performance
scores, eye-tracking and EEG- and fMRI-measures.
Secondary outcome
Not applicable
Background summary
Preliminary evidence suggest that the gamma-aminobutyric acid type A (GABA-A)
receptor is involved in conscious perception. The exact involvement of GABA-A
receptors in recurrent processing remains elusive and the link to conscious
experience severely underspecified. The aim of the proposed study is to provide
evidence for this hypothesis.
Study objective
The primary objective is to investigate the involvement of the GABA-A receptor
in behavioral and neural measures of conscious perception, cognition, and
decision-making.
Study design
This study will use a within-subject, double-blind, placebo-controlled
randomized crossover design.
Intervention
Participants will receive 1.5 mg lorazepam or placebo on two different test
sessions, in a randomized order.
Study burden and risks
Participants will have to visit the lab 3 times. One of these visits is the
initial intake session, the others are testing days. On these testing days,
participants will perform simple computer tasks, while their brain activity is
measured with EEG or fMRI. In addition, participants will receive 1.5 mg
lorazepam or placebo on each testing day. Before and after testing days,
participants have to adhere to some simple restrictions concerning the intake
of alcohol, drugs and caffeine and operating motorized vehicles.
The used product can cause side-effects, including drowsiness and dizziness.
Previous studies using single doses of this product show, however, that it is
well-tolerated. Considering the extensive exclusion criteria, screening
procedure, constant monitoring of participants and the fact that they only
receive single, subtherapeutic doses of these products, we do not expect any
serious side-effects.
Nieuwe achtergracht 129
Amsterdam 1001NK
NL
Nieuwe achtergracht 129
Amsterdam 1001NK
NL
Listed location countries
Age
Inclusion criteria
Healthy volunteers between 18 and 30 years old;
BMI between 18.5 and 30.
Exclusion criteria
Allergy for memantine, lorazepam, or one of the inactive ingredients of these
products;
Current or history of any medical or psychiatric disorder or disease.
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL86602.018.24 |